Favourable regulatory guidelines for designing and manufacturing of IVT injectables in the interest of patient safety is the primary driving factor for market growth. However, injectables are also associated with multiple risks or complications like inflammation and infection in the eye, vitreous haemorrhage and retinal detachment are expected to restrain the market growth. The global intravitreal (IVT) injectables market is poised to value over USD 5 billion by 2029 end. Insights on Global Intravitreal Injectables Market: 1. By Region • North America • Europe • Asia Pacific • Middle East & Africa • Latin America IVT injection is the most common eye treatment procedure in the U.S, this region dominates the global market. Furthermore, an increase in the geriatric population in not only North American but also in the European region is further fuelling the market growth in both the regions. India and China comprise of numerous patients suffering from diabetes mellitus which can also result in diabetic retinopathy which increases the demand for IVT injectables thus accelerating the market growth in the Asia Pacific region. 2. By Drug Class • Anti-VEGF • Antibiotics • Corticosteroids • Antifungals • Antivirals The anti-VEGF segment dominates the global market. The characteristics of anti-VEGF drugs are crucial with respect to the treatment of ocular diseases its ability to minimize fluid leakage that occurs while treating such diseases. Additionally, these drugs are capable of binding growth factors and in suppressing the formation of irregular RBCs in ocular diseases. Aforementioned, are the factors that drive this market segment resulting in its substantial growth. 3. By Indication • Diabetic Retinopathy • Macular Degeneration • Endophthalmitis • Retinal Vein Occlusions Macular degeneration, age-related macular degeneration, in particular, is primarily observed in the North American region which is a huge market scope and therefore the macular degeneration market segment dominates this market segment and this trend will continue during the forecast period considering the constant rise in the geriatric population. 4. By Distribution • Hospital Pharmacies • Retail Pharmacies • Drug Stores • Mail order Pharmacies Hospital pharmacies dominate the global market due to the amount of medical stock that these pharmacies possess. Additionally, the integration with hospitals makes it easy for the patients to access these medicines which are generally expensive in drug stores not associate with them and hence this market segment will continue to dominate the global market during the forecast period. Key Players: • Bausch & Lomb • Novartis AG • Allergan • F. Hoffmann-La Roche Ltd. • Thrombogenics Inc. • Alimera Sciences Allergan’s Ozurdex intravitreal implant is used for treating diabetic macular edema (DME) by injecting corticosteroids at regular intervals once it is implanted in the eye. The implantation process of Ozurdex is not time-consuming and the implant gets dissolve naturally without requiring any surgical procedures for its removal. These advantages of Ozurdex will help Allergan establish its market position. Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global intravitreal injectables market by region, by drug class, by indication, by distribution • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Middle East & Africa and Latin America • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com
Favourable regulatory guidelines for designing and manufacturing of IVT injectables in the interest of patient safety is the primary driving factor for market growth. However, injectables are also associated with multiple risks or complications like inflammation and infection in the eye, vitreous haemorrhage and retinal detachment are expected to restrain the market growth.
The global intravitreal (IVT) injectables market is poised to value over USD 5 billion by 2029 end.
Insights on Global Intravitreal Injectables Market: 1. By Region • North America • Europe • Asia Pacific • Middle East & Africa • Latin America IVT injection is the most common eye treatment procedure in the U.S, this region dominates the global market. Furthermore, an increase in the geriatric population in not only North American but also in the European region is further fuelling the market growth in both the regions.
India and China comprise of numerous patients suffering from diabetes mellitus which can also result in diabetic retinopathy which increases the demand for IVT injectables thus accelerating the market growth in the Asia Pacific region.
2. By Drug Class • Anti-VEGF • Antibiotics • Corticosteroids • Antifungals • Antivirals The anti-VEGF segment dominates the global market. The characteristics of anti-VEGF drugs are crucial with respect to the treatment of ocular diseases its ability to minimize fluid leakage that occurs while treating such diseases. Additionally, these drugs are capable of binding growth factors and in suppressing the formation of irregular RBCs in ocular diseases. Aforementioned, are the factors that drive this market segment resulting in its substantial growth.
3. By Indication • Diabetic Retinopathy • Macular Degeneration • Endophthalmitis • Retinal Vein Occlusions Macular degeneration, age-related macular degeneration, in particular, is primarily observed in the North American region which is a huge market scope and therefore the macular degeneration market segment dominates this market segment and this trend will continue during the forecast period considering the constant rise in the geriatric population.
4. By Distribution • Hospital Pharmacies • Retail Pharmacies • Drug Stores • Mail order Pharmacies Hospital pharmacies dominate the global market due to the amount of medical stock that these pharmacies possess. Additionally, the integration with hospitals makes it easy for the patients to access these medicines which are generally expensive in drug stores not associate with them and hence this market segment will continue to dominate the global market during the forecast period.
Key Players: • Bausch & Lomb • Novartis AG • Allergan • F. Hoffmann-La Roche Ltd. • Thrombogenics Inc. • Alimera Sciences Allergan’s Ozurdex intravitreal implant is used for treating diabetic macular edema (DME) by injecting corticosteroids at regular intervals once it is implanted in the eye. The implantation process of Ozurdex is not time-consuming and the implant gets dissolve naturally without requiring any surgical procedures for its removal. These advantages of Ozurdex will help Allergan establish its market position.
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the global intravitreal injectables market by region, by drug class, by indication, by distribution • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Middle East & Africa and Latin America • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com
OR